You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Claims for Patent: 7,196,205

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,196,205

Title:	Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
Abstract:	Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.
Inventor(s):	Siegel; Craig (Woburn, MA), Shayman; James A. (Ann Arbor, MI), Nelson; Carol A. (Westford, MA), Harris; David J. (Lexington, MA), Copeland; Diane P. (North Billerica, MA)
Assignee:	The Regents of the University of Michigan (Ann Arbor, MI) Genzyme Corporation (Cambridge, MA)
Application Number:	11/091,836
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,196,205
Patent Claims:	1. A compound represented by the following structural formula: ##STR00033## or a physiologically acceptable salt thereof. 2. A compound represented by the following structural formula: ##STR00034## or a physiologically acceptable salt thereof. 3. The compound of claim 1, wherein the compound has an enantiomeric excess of at least 10%. 4. The compound of claim 1, wherein the compound has an enantiomeric excess of at least 25%. 5. The compound of claim 1, wherein the compound has an enantiomeric excess of at least 50%. 6. The compound of claim 1, wherein the compound has an enantiomeric excess of at least 75%. 7. The compound of claim 1, wherein the compound has an enantiomeric excess of at least 90%. 8. The compound of claim 1, wherein the compound has an enantiomeric excess of at least 95%. 9. The compound of claim 1, wherein the compound has an enantiomeric excess of at least 99%. 10. The compound of claim 2, wherein the compound has an enantiomeric excess of at least 10%. 11. The compound of claim 2, wherein the compound has an enantiomeric excess of at least 25%. 12. The compound of claim 2, wherein the compound has an enantiomeric excess of at least 50%. 13. The compound of claim 2, wherein the compound has an enantiomeric excess of at least 75%. 14. The compound of claim 2, wherein the compound has an enantiomeric excess of at least 90%. 15. The compound of claim 2, wherein the compound has an enantiomeric excess of at least 95%. 16. The compound of claim 2, wherein the compound has an enantiomeric excess of at least 99%.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.